Related Experiment Video

Updated: Aug 6, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

Predicting drug metabolism induction in silico

Daniela Schuster1, Theodora M Steindl, Thierry Langer

  • 1Department of Pharmaceutical Chemistry, Institute of Pharmacy, Innrain 52c, University of Innsbruck, and Center for Molecular Biosciences Innsbruck, CMBI, A-6020 Innsbruck, Austria.

Current Topics in Medicinal Chemistry
|August 22, 2006
PubMed

Insights

Understanding how xenobiotics induce drug-metabolizing enzymes and transporters is crucial for drug development. This review explores in silico simulation tools for predicting these interactions and avoiding adverse drug-drug interactions.

Area of Science:

  • Pharmacology
  • Drug Metabolism and Transport
  • Computational Chemistry

Background:

  • Xenobiotics can induce drug-metabolizing enzymes and transporters, significantly impacting drug efficacy and safety.
  • Activation of orphan nuclear receptors is a key mechanism underlying this induction.
  • Altered drug levels due to enzyme and transporter induction can lead to dangerous drug-drug interactions.

Purpose of the Study:

  • To provide an introduction to the induction of drug metabolism and transport.
  • To review computer-assisted molecular modeling prediction techniques for induction.
  • To discuss the applicability, limitations, and success stories of these in silico tools.

Main Methods:

  • Review of current literature on xenobiotic-induced enzyme and transporter modulation.
  • Focus on in silico prediction techniques, including molecular modeling.
  • Analysis of case studies and documented success stories.

Main Results:

  • In silico tools are valuable for anticipating induction effects early in drug design.
  • These computational methods aid in avoiding potential drug-drug interactions.
  • The review highlights the practical application and limitations of predictive modeling.

Conclusions:

  • Reliable in silico simulation tools are essential for modern drug development.
  • Predictive modeling aids in mitigating risks associated with drug metabolism and transport induction.
  • Understanding and predicting these interactions improves drug safety and efficacy.

More Related Videos

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs01:21

Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs

A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in determining the metabolic...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Factors Affecting Drug Biotransformation: Biological01:19

Factors Affecting Drug Biotransformation: Biological

Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...